Value proposition

Single-cell CRISPR screening - a powerful approach to fast-forward target identification and drug discovery

Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens.

Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions (MoA) of drugs. Each screening project is customized to the specific needs of our clients and we perturb cells with CRISPR KO, CRISPR interference or CRISPR activation coupled to high-content read-outs such as fitness, FACS and single-cell transcriptomics. Notably, we offer single-cell CRISPR screens (CROP-Seq) in cancer cells and primary immune cells, including primary human T cells to support biotech and pharma companies striving to develop novel CAR-T and TCR-T cell therapeutics.

Functional Genomics, Pooled CRISPR Screening, Early R&D, Target Identification, Drug Discovery, T Cell Biology, Immunology, Oncology, Transcriptomics, Single-Cell RNA Sequencing, Flow Cytometry, Genomics Service Provider, Assay Development, Project Management, Customized CRISPR gRNA Design, Targeted Sequencing, Bioinformatics, CRISPR KO Screens, and CRISPR Interference Screens